| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/05/2001 | WO2001002019A3 Control of gene expression |
| 07/05/2001 | WO2001000854A3 Chimeric proteins mediating targeted apoptosis |
| 07/05/2001 | WO2001000825A3 Human chromosome 15 and 16 bardet-biedl syndrome polynucleotides and polypeptides and methods of use |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2001000822A3 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 07/05/2001 | WO2001000654A3 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 07/05/2001 | WO2001000638A3 Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |
| 07/05/2001 | WO2000078795A3 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) |
| 07/05/2001 | WO2000078332A3 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/05/2001 | WO2000078331A3 Il6ril6 chimera for the treatment of neurodegenerative diseases |
| 07/05/2001 | WO2000076552A8 Methods and compositions for control of bone formation via modulation of leptin activity |
| 07/05/2001 | WO2000074650A3 Implantable gel compositions and method of manufacture |
| 07/05/2001 | WO2000073478A3 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 07/05/2001 | WO2000073348A3 Methods and compositions for inhibiting neoplastic cell growth |
| 07/05/2001 | WO2000071679A3 Human oxidoreductase proteins |
| 07/05/2001 | WO2000071578A3 New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins |
| 07/05/2001 | WO2000070046A3 Secreted polypeptides and corresponding polynucleotides |
| 07/05/2001 | WO2000069896A3 Molecular interactions in haematopoietic cells |
| 07/05/2001 | WO2000066721A3 Decreasing adipose mass by altering rsk2 activity |
| 07/05/2001 | WO2000066138A3 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 07/05/2001 | WO2000061622A3 Genes associated with diseases of the kidney |
| 07/05/2001 | WO2000061621A3 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
| 07/05/2001 | WO2000059942A3 Human obesity protein binding protrein-2 homolog and uses thereof |
| 07/05/2001 | WO2000035945A8 Cyclic peptide antifungal agents having a sugar substituent |
| 07/05/2001 | WO2000034483A9 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 07/05/2001 | WO2000023114A9 Polymer conjugates of interferon beta- 1a and their uses |
| 07/05/2001 | WO2000018799A9 Artemin, a novel neurotrophic factor |
| 07/05/2001 | WO2000017356A9 Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
| 07/05/2001 | WO2000017334A9 Analysis of ligand activated nuclear receptors i(in vivo) |
| 07/05/2001 | WO2000006728A8 Phosphorylation effectors |
| 07/05/2001 | US20010007037 Solid phase peptide synthesis; in situ generation of amino acid chloride by deblocking; coupling sterically hindered amino acid residues |
| 07/05/2001 | US20010007025 Antisense modulation of bcl-x expression |
| 07/05/2001 | US20010007023 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010007019 Useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing |
| 07/05/2001 | US20010007018 Methods and compositions for treating preterm labor and premature rupture of fetal membranes |
| 07/05/2001 | US20010007017 For preventing AIDS or slowing down its progression |
| 07/05/2001 | US20010007016 Analgesics, especially for cancer |
| 07/05/2001 | US20010007015 Can be used as the basic structures (template molecules) for inhibiting and analysing amyloid formation and cytotoxicity in amyloid illnesses |
| 07/05/2001 | US20010006989 Pre-polymerization, monomer(s) dissolved in water-miscible aprotic organic solvent forming non-solvent mixture of polymer; prophylactic or curative antibiotics or antiseptic agents |
| 07/05/2001 | US20010006967 Administering an analgesic amount of tramadol and an amount of an excitatory opioid receptor antagonist, e.g naltrexone, nalone, to lessen the antianalgesia, hyperalgesia, hyper-excitability, physical dependence and or tolerance |
| 07/05/2001 | US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity |
| 07/05/2001 | US20010006954 Synthetic DNA comprising a radiation responsive enhancer-promoter operatively linked to a polypeptide encoding region linked to a transcription terminating region; regulating gene expression and inhibiting tumor growth |
| 07/05/2001 | US20010006951 Method of intranasal gene transfer for protection against respiratory infection |
| 07/05/2001 | US20010006949 Methods and compositions for producing cells resistant to apoptosis |
| 07/05/2001 | US20010006943 Protracted GLP-1 compositions |
| 07/05/2001 | US20010006942 Inducing an immune response against a chemokine receptor molecule by administering an immunogenic chemokine receptor polypeptide from an extracellular region of a chemokine receptor molecule; treating inflammation, multiple sclerosis |
| 07/05/2001 | US20010006940 Human chorionic gonadotrophin (hCG) used to treat or prevent tumors, multiple sclerosis, inflammation or angiogenesis-dependent diseases |
| 07/05/2001 | US20010006939 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| 07/05/2001 | US20010006816 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses |
| 07/05/2001 | US20010006815 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses |
| 07/05/2001 | US20010006814 Chemical modification |
| 07/05/2001 | US20010006806 Methods for treating sepsis |
| 07/05/2001 | US20010006799 Histidine kinase polypeptides |
| 07/05/2001 | US20010006798 Novel FtsL |
| 07/05/2001 | US20010006796 Nucleic acids encoding variant human vectors |
| 07/05/2001 | US20010006793 Modulators of eukaryotic caspases |
| 07/05/2001 | US20010006792 Immunomodulatory properties |
| 07/05/2001 | US20010006790 Ihhibition of amylin release |
| 07/05/2001 | US20010006788 Complexing glycoprotein with antibodies; medical diagnosis |
| 07/05/2001 | US20010006776 Methods for treatment of hiv and other infections using a t cell or viral activator and anti-retroviral combination therapy |
| 07/05/2001 | US20010006682 Administering parenterally to the patient having suppressed immune system, an effective treatment amount of Product R, a peptide-nucleic acid preperation, alone or in combination with one or more immuno-modulators |
| 07/05/2001 | US20010006681 Chemokine inhibition of immunodeficiency virus |
| 07/05/2001 | US20010006656 Comprising an aerosol formulation of a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, said HMG-CoA reductase inhibitor being present at a concentration of less than 0.1 mg |
| 07/05/2001 | US20010006642 Delivering antigens or biologically active polypeptides to a subject in need of same by administering to the subject a non-invasive or non-pathogenic bacterium which expresses the antigens or polypeptides |
| 07/05/2001 | US20010006640 Compounds and methods to inhibit or augment an inflammatory response |
| 07/05/2001 | US20010006638 Treatment of immune suppression by infusing a dose of selected monoclonal antibodies that inhibit overproduction of lymphocyte function-related antigen 1 (lfa-1) on cd8cells |
| 07/05/2001 | US20010006637 Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient |
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | US20010006631 Alloactivated lymphocytes in a pharmaceutical excipient; immunotherapy |
| 07/05/2001 | US20010006630 Biological material such as cell, and purified extracellular matrix degrading enzyme externally adhered thereto; for treating mucopolysaccharidoses, cystic fibrosis, parkinson's disease, Gaucher's syndrome and osteogeneis imperfecta |
| 07/05/2001 | US20010006629 Recombinant adenoviral vector and methods of use |
| 07/05/2001 | US20010006620 Such a hirudin or oral thrombin inhibitor, by determining from the ratio of the dose given to the measured ecarin clotting time using a computer statistical analysis program |
| 07/05/2001 | DE19960924A1 Amphiphile Polyamine, deren Anwendungen und Verfahren zu ihrer Synthese Amphiphilic polyamines, their applications and methods for their synthesis |
| 07/05/2001 | CA2397955A1 Method for pr-39 peptide mediated selective inhibition of i.kappa.b.alpha. degradation |
| 07/05/2001 | CA2397710A1 Streptococcus pyogenes virulence genes and proteins and their use |
| 07/05/2001 | CA2396533A1 Treatment of ischemic brain injuries with brain targetted antioxidant compounds |
| 07/05/2001 | CA2396039A1 Gfr.alpha.1-ret specific agonists and methods therefor |
| 07/05/2001 | CA2396029A1 Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope |
| 07/05/2001 | CA2395996A1 Neuroprotective drug |
| 07/05/2001 | CA2395950A1 Cells capable of differentiating into heart muscle cells |
| 07/05/2001 | CA2395839A1 Gene therapy for congestive heart failure |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395535A1 Method for the production of vitamin a |
| 07/05/2001 | CA2395454A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | CA2395320A1 Therapeutic uses of lna-modified oligonucleotides |
| 07/05/2001 | CA2395305A1 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395276A1 Identification of novel splice variants of the human catalytic subunit c.beta. of camp-dependent protein kinase and the use thereof |
| 07/05/2001 | CA2395275A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 07/05/2001 | CA2395273A1 A novel isoform of human camp-dependent protein kinase, c.alpha.-s, localizes to sperm midpiece and the use thereof |
| 07/05/2001 | CA2395236A1 Basolateral sorting signal and inhibitors thereof |
| 07/05/2001 | CA2395143A1 Novel cdnas encoding catenin-binding proteins with function in signalling and/or gene regulation |
| 07/05/2001 | CA2395003A1 Dioxygenases catalyzing the asymetric cleavage of beta-carotene |
| 07/05/2001 | CA2394880A1 Activation and inhibition of the immune system |
| 07/05/2001 | CA2394758A1 Histidine-containing copolymers enhance pharmaceutical agent delivery |
| 07/05/2001 | CA2394295A1 Antibodies against plasma cells |
| 07/05/2001 | CA2393529A1 Inhibitors of complement activation, their preparation and use |
| 07/05/2001 | CA2392703A1 Human heparanase-related polypeptide and nucleic acid |
| 07/04/2001 | EP1113073A2 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |